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Abstract
The polysaccharide-rich fungal cell wall provides pathogen-specific targets for antifungal therapy 
and distinct molecular patterns that stimulate protective or detrimental host immunity. The 
echinocandin antifungal caspofungin inhibits synthesis of cell wall β-1,3-glucan and is used for 
prophylactic therapy in immune suppressed individuals. However, breakthrough infections with 
fungal pathogen Aspergillus fumigatus are associated caspofungin prophylaxis. In this study, we 
report in vitro and in vivo increases in fungal surface chitin in A. fumigatus induced by 
caspofungin that was associated with airway eosinophil recruitment in immune competent and 
neutropenic mice with invasive pulmonary aspergillosis (IA). More importantly, caspofungin 
treatment of mice with IA resulted in a pattern of increased fungal burden and severity of disease 
that was reversed in eosinophil-deficient mice. In addition, the eosinophil granule proteins major 
basic protein and eosinophil peroxidase were more frequently detected in the bronchoalveolar 
lavage fluid of lung transplant patients diagnosed with IA that received caspofungin therapy when 
compared to azole-treated patients. Eosinophil recruitment and inhibition of fungal clearance in 
caspofungin-treated mice with IA required RAG1 expression and γδ T cells. These results identify 
an eosinophil-mediated mechanism for paradoxical caspofungin activity and support the future 
investigation of the potential of eosinophil or fungal chitin-targeted inhibition in the treatment of 
IA.
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Introduction
The ubiquitous filamentous fungus Aspergillus fumigatus is an opportunistic pathogen and 
aeroallergen source capable of inducing lung inflammation, colonization, and/or invasive 
infection contingent on the level of immune capability of the host (1–3). The incidence of 
invasive pulmonary aspergillosis (IA) has increased along with the use of immune 
suppressive and myeloablative therapies. Mortality in immune suppressed patients with IA 
may reach 90% depending on the population, and current options for antifungal therapy are 
not highly effective and often require prolonged administration (3–5). It is therefore of 
paramount importance for clinicians and researchers to increase their understanding of the 
underlying biological mechanisms that reduce antifungal efficacy in order to facilitate the 
development of new and improved therapies.
The cell wall/membrane of A. fumigatus is comprised of multiple structures distinct from 
mammalian cell membranes, thus offering pathogen-specific targets for antifungal therapy 
and host immunity (6). Voriconazole or other triazole drugs that inhibit synthesis of fungal 
cell membrane ergosterol are currently recommended for primary or empiric therapy (7, 8). 
However, fungal azole resistance in IA patients is increasing, possibly due to increased 
agricultural use of fungicidal azole compounds (9–12). In contrast to azoles, the 
echinocandin class of antifungals inhibit the synthesis of the fungal cell wall polysaccharide 
β-1,3-glucan (13). Administration of echinocandins is indicated for aspergillosis patients 
that do not respond to azole therapy alone (5, 14). In addition, echinocandins such as 
caspofungin may be used as a part of a prophylactic regimen for patients that are highly 
susceptible to fungal infections (15). However, among susceptible patients receiving 
prophylactic caspofungin, a commonly reported “breakthrough” fungal infection was 
aspergillosis (16–19). In a mouse model of IA, lung fungal burden was decreased at lower 
caspofungin doses, but paradoxically increased at the highest dose (20). Thus, in some 
patients caspofungin/echinocandin therapy may be less effective at preventing or treating A. 
fumigatus infection in comparison to other fungal pathogens.
The early lung immune response to inhalation of A. fumigatus conidia is shaped by innate 
recognition of fungal cell wall polysaccharides, particularly β-1,3-glucan and chitin (21–23). 
In dormant conidia, these covalently-linked sugars are masked by a hydrophobic rodlet layer 
that breaks down upon swelling and germination, thus initiating recognition via innate 
receptors on resident tissue macrophages and newly recruited inflammatory cells (24). 
Notably, early recognition of β-1,3-glucan and chitin in A. fumigatus conidia initiates 
distinct immune profiles (23). β-1,3-glucan recognition by dectin-1 promotes type 1 and 
IL-17-skewed immune responses while chitin promotes type 2 immunity that is detrimental 
in response to fungal pathogens but are otherwise protective for chitin-containing helminths 
(25–33). Notably, mouse inhalation of purified chitin induced lung accumulation of 
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eosinophils and alternate activation of lung macrophages that was dependent on IL-5 and 
IL-13 secretion by type 2 innate lymphoid cells (31, 34). We previously observed that 
eosinophils in particular mediated type 2 pathology in a mouse model of IA; their absence 
resulted in increased fungal clearance (30). Although eosinophils were detrimental in this 
setting, the potential for eosinophil-mediated pathology in clinical invasive aspergillosis 
remains less clear.
A significant body of work has described the cell wall of A. fumigatus as exhibiting 
plasticity marked by structural changes in response to mutation and environmental stress 
(reviewed by Latge and Beauvais (35)). Furthermore, environmental stressors are not limited 
to outdoor and indoor environments, but also include the microenvironment encountered in 
vivo during host lung colonization and infection. Not surprisingly, antifungal drugs induce a 
significant amount of stress by directly inhibiting cell wall or membrane synthesis. For 
example, direct inhibition of the β-1,3-glucan synthesis pathway by in vitro growth in the 
presence of caspofungin resulted in a cell wall architecture characterized by increased levels 
of chitin in A. fumigatus (36, 37). However, a connection between increased caspofungin-
mediated chitin exposure and increased eosinophil activation and pathology has not been 
described. Two clinical reports described eosinophilia in caspofungin-treated patients with 
IA, although a mechanism explaining these observations was neither proposed nor examined 
(38, 39). When considered together, these results suggest that caspofungin has the potential 
to increase detrimental eosinophilia in patients with IA, although direct evidence supporting 
this hypothesis remains lacking.
In this study, we demonstrate a clinical relevance for this relationship by demonstrating that 
caspofungin treatment increases eosinophil recruitment and pathology in a mouse model 
invasive aspergillosis. Furthermore, we identify a role for γδ T cells in this response. We 
also extend our findings to IA patients by comparing the levels of eosinophil activation 
markers in the bronchoalveolar lavage fluid (BALF) of patients treated with azole drugs with 
those that received a combination therapy that included caspofungin. Our results suggest a 
mechanism for caspofungin-mediated increases in fungal chitin and detrimental eosinophil 
recruitment in invasive aspergillosis.
Materials and Methods
Growth and handling of fungi
Aspergillus fumigatus (Af293) was purchased from the Fungal Genetics Stock Center. Fungi 
were cultured on malt extract agar (MEA). Conidia were isolated from culture plates kept at 
RT for 14 days by applying and gently shaking 1g of glass beads (0.5 mm, BioSpec 
Products), then placed in suspension by pouring the beads into a tube with sterile phosphate 
buffered saline (DPBS). For mouse aspiration, conidia were harvested using glass beads and 
resuspended in DPBS. The beads were then vortexed and the supernatant containing the 
conidia was removed, diluted and counted with a hemacytometer and used for aspiration. To 
determine the effect of capsofungin on conidial chitin exposure, the Af293 isolate was 
cultured on MEA plates containing 16ug/ml caspofungin diacetate (Sigma) and incubated at 
37°C for 4 days. For flow cytometric analysis of conidia, harvested conidia were swollen in 
RPMI for 4 hours at 37°C and subsequently fixed with 4% paraformaldehyde. Swollen and 
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fixed conidia were washed with ammonium chloride and DPBS and resuspended in DPBS 
for surface staining and flow cytometric analysis. For surface staining, swollen conidia was 
stained with carbohydrate binding lecithin, Wheat Germ Agglutinin (WGA; conjugated with 
APC) for surface chitin detection and analyzed on flow cytometry for quantification.
Mouse infection, sacrifice, histological staining, and collection of BALF
BALB/c or C57BL6/J mice were obtained from Envigo or Jackson Laboratory, while 
ΔdblGATA1, and TCRδ−/− mice aged 5 weeks were obtained from Jackson Laboratory. 
IL-4 GFP-reporter mice (4get) were previously obtained from Dr. Richard Locksley. Mice 
were allowed to rest 2–4 weeks prior to experiments. A subset of mice were bred at the 
IUSM-Terre Haute animal facility with offspring used in subsequent experiments at 7–10 
weeks of age.
To induce invasive pulmonary aspergillosis in mice, neutrophils were depleted by 
intraperitoneal injection of 0.25 mg α-Ly6G (1A8; BioXCell) 24 hours before and after 
infection. Neutropenic mice were infected with 5x106 condia of A. fumigatus isolates by 
involuntary aspiration. Caspofungin was prepared in sterile DPBS at 5mg/Kg (high dose) or 
1mg/Kg (low dose) (40) and was injected i.p. on a daily basis until mice were harvested. In 
some experiments, infected mice were monitored for survival or changes in disease using a 
five-point scale: 0) healthy 1) minimal disease (e.g. ruffled fur), 2) moderate disease (e.g. 
ungroomed, hunched), 3) severe disease (e.g. severely hunched, changes in eye color, low 
motility), and 4) moribund or deceased. Mice were sacrificed with sodium pentobarbitol, 
and lungs were perfused with 10ml phosphate buffered saline (PBS). Bronchoalveolar 
lavage fluid (BALF) was collected from the perfused lungs as previously described (41). For 
paraffin-embedded histological preparation, lungs were perfused with PBS followed by 
perfusion and inflation of the lungs with 10% buffered formalin phosphate (Fisher 
Scientific). To visualize lung infiltration by inflammatory cells, hematoxylin and eosin 
(H&E) stains were prepared and analyzed, and Gomori’s modified methanamine silver 
(GMS) stain was used for visualization of fungal germination in the lungs. Tissue 
processing, embedding, and staining was performed at Terre Haute Regional Hospital or at 
IUSM-TH. For frozen section preparation, lungs were perfused with 30% sucrose and 
inflated with 1:1 OCT (TissueTek) and immersed in 30% sucrose. After gradient freezing by 
embedding in OCT the tissue was kept frozen until sectioning. Lungs were cut in 5–10 μm 
using a cryostat (Avantik) and used for immunofluorescence microscopy. All animal 
procedures were approved by the Animal Care and Use Committee of Indiana State 
University, the host campus of IUSM-Terre Haute.
Flow cytometric analysis of bronchoalveolar lavage fluid and lung homogenates
BALF cell composition was determined by flow cytometric analysis of recovered lavage 
cells in suspension. BALF was centrifuged for 5 min at 1500 rpm, the supernatant removed, 
and the cell pellet resuspended and washed in 1ml of FACS buffer (Phosphate Buffered 
Saline, 5% fetal bovine serum, 0.05% sodium azide). The washed pellet was resuspended 
and stained in a solution containing FACS buffer with 10% rat serum, Fc-receptor blocking 
antibody (clone 24G2) and the following antibodies: rat-anti-mouse Ly-6G-FITC, rat-anti-
mouse Siglec-F-PE, pan-leukocyte rat-anti mouse CD45-PerCP, and rat-anti-mouse CD11c-
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APC. For γδ T cell staining the following antibodies were used; rat-anti-mouse CD3-PeCy7 
and TCRδ-PE (BD Biosciences). After staining, cells were washed and fixed with BD 
Cytofix, except for cells from 4get GFP reporter mice that were resuspended in FACS buffer 
and subsequently analyzed by flow cytometry. Flow cytometric data acquisition was 
performed on a Guava EasyCyte 8HT (EMD Millipore).
Immunofluorescence microscopy
6–8μm frozen sections of infected lungs were used for immunofluorescence staining. For 
fungal surface stain, calcofluor white (CFW; Sigma-Aldrich) was used to visualize surface 
chitin deposition in fungal hyphae. Rabbit anti-mouse CCR3 (Thermofisher) was used to 
visualize eosinophils with a goat anti-rabbit Dy-Light 488 (Abcam) secondary antibody. 
Briefly, sections were prepared by fixing the frozen sections in 4% paraformaldehyde at 
room temperature. Slides were stained with anti-CCR3 or CFW after blocking the sections 
with 10% goat serum for 1hr at 4°C followed by multiple washes with PBS and a 1 hour 
incubation with secondary antibody.
Total RNA processing and gene expression analysis
Lungs were removed and flash frozen in liquid nitrogen for RNA extraction. Total RNA was 
extracted from whole lungs homogenized in Trizol reagent (Invitrogen). Following the 
aqueous upper phase separation further RNA purification was performed using Qiagen 
RNEasy column with DNAse treatment per manufacturer’s recommendations. 2ug of total 
RNA was transcribed using High-capacity cDNA synthesis kit (Life Technologies) 
according to manufacturer’s protocol. For qPCR, Power-Up Sybr Green PCR Mastex Mix 
(Applied Biosystems) was used with Mxp3500 Real-time PCR system (Agilent). Select 
cytokine expression primers were obtained from SABiosciences.
Patient samples and ELISA
BALF was previously collected from lung transplant recipients at Royal Brompton and 
Harefiled NHS Foundation Trust (London, UK), with appropriate ethical approval (RBH/
AS1) (42). Along with BALF, information regarding clinical diagnoses and antifungal 
pharmacotherapy were obtained. For detection of eosinophil peroxidase (EPO) and human 
major basic protein (MBP) in BAL of transplant patients, human EPO and MBP ELISA kits 
were purchased from NovateinBio (Woburn MA) and used according to manufacturer’s 
protocol. All samples were run in duplicates. Patients with a clinical diagnosis of fungal 
infection were further divided into two groups, those with caspofungin therapy alone or in 
combination with other antifungal drugs and patients that only received azole therapy.
Data analysis methods
Analysis of mouse flow cytometric data was performed with FlowJo software (TreeStar). 
GraphPad Prism was used for generation of graphs and Figures and for statistical analyses 
(GraphPad Software). Unpaired t-tests were used to measure statistical significance when 
two groups were compared, and one or two-way analysis of variance (ANOVA) tests were 
used along with Tukey’s or Sidak’s post-tests for multiple comparisons, respectively. 
Survival curves were analyzed with Mantel-Cox log-rank tests. Patient data from this study 
Amarsaikhan et al. Page 5
J Immunol. Author manuscript; available in PMC 2018 July 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
was analyzed by ANOVA using generalized estimating equation models, which allow the 
use of non-normal data by determining the best distribution of fit. Patient data were analyzed 
using SAS v9.4 (SAS Institute). Differences between experimental groups that resulted in a 
p-value of less than 0.05 were considered significant.
Results
Caspofungin increases fungal chitin exposure in vitro and in the lungs of mice with 
invasive aspergillosis
Previous studies have reported increased A. fumigatus chitin expression when β-1,3-glucan 
synthesis is inhibited by caspofungin (36, 37). To confirm if caspofungin increases chitin 
exposure in germinating conidia, we cultured and germinated the clinical isolate Af293 
(low/normal chitin expressing (43)) in the presence or absence of caspofungin and 
subsequently stained with the chitin-binding wheat germ agglutinin (WGA) for flow 
cytometric analysis. We observed that growth in the presence of caspofungin increased 
WGA staining on germinating conidia (Figs. 1A and 1B). To determine if caspofungin 
therapy in invasive infection is associated with increased fungal chitin exposure in vivo, we 
infected neutropenic BALB/c mice with Af293 conidia and compared lung tissue sections of 
caspofungin-treated and untreated mice at day 3 post-infection (model timeline in Fig. 1C). 
Compared to untreated mice, fungi in the lungs of caspofungin-treated (5mg/Kg) mice with 
IA displayed dysmorphic growth with short, thickened hyphae and swollen or burst hyphal 
tips (Fig. 1D). Fluorescence staining of the lung tissues with the chitin-binding calcofluor 
white resulted in an increased intensity of tissue-invading hyphae in mice treated with 
caspofungin when compared to controls (Fig. 1E and inset, bottom left). In addition, CCR3+ 
cells were observed within areas of hyphal growth in drug-treated and untreated mice (Fig. 
1E). These findings demonstrate that pharmacological targeting of β-1,3-glucan synthesis by 
caspofungin results in increased chitin exposure and/or deposition on the surface of A. 
fumigatus in vitro and in vivo.
Caspofungin treatment is associated with AMCase-sensitive eosinophil recruitment in 
mice with IA
Results of our previous work suggested that eosinophils are detrimental to protection in 
invasive aspergillosis in mice with Th2-skewed immunity (30). However, a high-chitin 
expressing isolate was used for exposures and infection that not only contained more chitin 
than commonly used clinical isolates such as Af293, but additionally displayed decreased 
virulence likely due to a decreased growth rate (43). We therefore aimed to determine if a 
pharmacologically mediated increase in chitin expression in the Af293 isolate in the lungs at 
the site of infection would result in a reciprocal increase in eosinophils in neutropenic 
BALB/c mice with IA. Seventy-two hours post-infection, we observed increased airway 
eosinophils in caspofungin-treated mice in comparison to untreated mice, while total 
leukocytes remained unchanged (Figs. 2A–C). Furthermore, airway eosinophil recruitment 
was partially decreased in caspofungin-treated mice that constitutively express acidic 
mammalian chitinase (AMCase; SPAM transgenic) when compared to non-transgenic 
littermates (Fig 2E). More specifically, a significant decrease was observed in the frequency 
of eosinophil in SPAM transgenic mice, while the total number of cells was not significant, 
Amarsaikhan et al. Page 6
J Immunol. Author manuscript; available in PMC 2018 July 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
possibly due to modulation of the number of total leukocytes in SPAM mice (Figs 2D, 2E). 
When considered together, these results suggest that caspofungin enhances chitin-mediated 
lung eosinophil recruitment in mice with IA.
Detection of eosinophil activation in caspofungin-treated patients with fungal infection
In patients with allergic or hypereosinophilic diseases, serum levels of eosinophil granule 
proteins were significantly increased and were correlated with inflammation and disease 
severity (44–47). We therefore appropriated this strategy to compare levels of the eosinophil 
granule proteins major basic protein (MBP) and eosinophil peroxidase (EPX) in 
bronchoalveolar lavage fluid (BALF) samples from lung transplant patients with or without 
a clinical diagnosis of Aspergillus infection (42). We further grouped these samples based on 
the associated antifungal therapy: those infected patients that received azole therapy alone 
compared to those that received caspofungin (alone or in combination with azoles). Despite 
a large range of activation among patients, MBP and EPX proteins were more frequently 
detected in the BALF of individuals that received caspofungin therapy in comparison to 
azole-treated patients (Figs. 3A and 3B). Therefore, our results in patients and mice with 
aspergillosis suggest that caspofungin therapy is associated with increased lung eosinophil 
recruitment and activation.
Lack of effective caspofungin-mediated fungal clearance in invasive aspergillosis is 
reversed in eosinophil-deficient mice
We next wanted to determine if eosinophils increased pathology and inhibited fungal 
clearance in caspofungin-treated mice with IA. By five days post-infection, all wild-type, 
caspofungin-treated BALB/c mice with IA had succumbed to infection, whereas half of 
caspofungin-treated eosinophil-deficient (ΔdblGATA1) mice survived to eight days (Fig. 
4A). Similarly, disease severity was markedly increased in wild-type mice treated with 
caspofungin in comparison to untreated wild-type and eosinophil−/− mice, while significant 
improvement was observed with caspofungin in the absence of eosinophils (Fig. 4B). 
Furthermore, eosinophil-deficient mice exhibited improved fungal clearance with 
caspofungin treatment, while wild-type mice did not (Figs. 4C, D), and this phenotype was 
further confirmed with the observation and quantification of fungal staining in GMS 
histological sections that showed significant fungal clearance only in capsofungin-treated, 
eosinophil-deficient BALB/c mice (Figs. 4E, F). Decreased fungal burden was also observed 
in C57BL/6-background eosinophil-deficient ΔdblGATA1 mice when compared to wild-type 
B6 mice (Supplemental Fig. S1C), although total leukocyte and eosinophil recruitment were 
not significantly increased in B6 mice as in their BALB/c counterparts (Figs. S1A and S1B). 
A decrease in fungal burden or eosinophil recruitment was not evident in dectin-1-deficient 
mice (B6 background) treated with caspofungin, suggesting that β-glucan recognition does 
not play a major role in paradoxical caspofungin activity in neutropenic mice with IA 
(Supplemental Figs. S1D–F). Furthermore, BALB/c mice treated with a lower dose 
(1mg/Kg) of caspofungin did not exhibit increased eosinophil recruitment or increased 
fungal burden (Figs S1G–H). These results indicate that the increased disease severity and 
fungal burden in caspofungin-treated mice is dependent on antifungal dose and the presence 
of eosinophils.
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Caspofungin-increased eosinophil recruitment requires RAG1 expression
Innate lung eosinophil recruitment in response to instillation of chitin particles was not 
dependent antigen receptor-rearranged lymphocytes that require expression of the 
recombinase activating gene 1 (RAG1) for development (31). Since we observed increased 
fungal chitin and eosinophil-mediated pathology in caspofungin-treated mice with IA, we 
aimed to determine if this phenotype in our model was also independent of RAG1 
expression. In infected RAG1−/− (BALB/c background) mice, we observed no difference in 
disease severity or fungal burden between control and caspofungin-treated mice (Figs. 5A, 
5B). Furthermore, airway eosinophil recruitment was not increased by caspofungin 
treatment (Fig. 5C). Thus, in contrast to results with chitin particles, RAG1 expression is 
required for the observed increase in eosinophil recruitment in response to A. fumigatus 
infection.
Modulation of CD3+TCRδ+ cells in caspofungin-treated mice with IA
The requirement for RAG1 expression for eosinophil-mediated pathology suggests a role for 
γδ T cells, iNKT cells, or conventional αβ T cells that are absent in RAG1-deficient mice. 
Of these subsets, γδ T cells were activated by inhalation of chitin particles and are capable 
of initiating early type 2 immune responses and eosinophil recruitment via secretion of IL-4 
(34, 48, 49). Therefore, we wanted to determine if lung γδ T cells were increased in 
caspofungin-treated mice with IA or exhibited increased IL-4 activation at 48 hours post-
infection when compared to infected, untreated mice. Unexpectedly, CD3+TCRδ+ cells 
were decreased in the lungs of infected mice that received caspofungin treatment (Figs. 6A 
and 6B). Furthermore, very few IL-4/GFP+ reporter activated (“4get” (50)) γδ T cells were 
detected regardless of caspofungin treatment (Fig. 6C and data not shown). These results 
suggest that γδ T cells are either decreased or decrease their surface TCR/CD3 expression, 
and do not display increased IL-4 gene activation in caspofungin-treated mice with IA.
Eosinophil recruitment and fungal burden are decreased by caspofungin treatment in γδ T 
cell-deficient mice with invasive aspergillosis
Although we detected fewer CD3+TCRδ+ cells in the lungs of caspofungin-treated mice, 
this result does not preclude an involvement of γδ T cells in caspofungin-driven eosinophil 
pathology of IA, as T cells are known to decrease surface expression of the TCR/CD3 
complex upon activation in order to prevent overstimulation (51–53). We therefore 
determined if γδ T cells were required for airway eosinophil recruitment during invasive 
infection. Interestingly, caspofungin-treated γδ T cell-deficient mice exhibited a marked 
increase in survival and decrease in fungal burden as measured by quantitative PCR of 
fungal DNA or quantification of fungal staining on histological sections in comparison to 
untreated mice (Figs. 7A–7C, with inset). Furthermore, in contrast to wild-type C57BL/6 
and dectin-1 deficient mice (Figs. S1 A, B, D, and E), airway eosinophils were decreased in 
γδ T cell deficient mice that received caspofungin treatment, while the total number of 
airway cells remained unchanged (Figs 7D and 7E). These results suggest that γδ T cells act 
as regulators of eosinophil recruitment and pathology in invasive aspergillosis.
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Effects of caspofungin treatment and requirement for γδ T cells in lung expression of 
immunomodulatory genes in mice with IA
Our results demonstrate a role for γδ T cells in eosinophil recruitment and pathology of A. 
fumigatus infection. How γδ T cells promote IA pathology remains less clear. In an 
experimental model of allergy, IL-4 secretion by γδ T cells promoted eosinophil recruitment 
(48). However, our results with IL-4 reporter mice indicated very few IL-4+ γδ T cells in the 
lungs of mice with IA (Fig. 6C). Using quantitative RT-PCR on lung tissue, we aimed to 
determine if expression of other genes associated with type 2 immune, γδ T cell activation, 
or chitin responses were modulated in response to caspofungin treatment in the presence or 
absence of γδ T cells at 48 hours post-infection. In response to caspofungin treatment, wild-
type mice with IA did not significantly modulate transcription of the cytokines/chemokines 
IL-4, IL-5, IL-17A, IL-22, CCL11, or CCL22 (Fig. 8A). Likewise, expression of the 
alternate activation marker of macrophages, Arginase-1, the chitinases AMCase and 
chitrosiadase (Chit1), and the chitinase-like proteins BRP39 and Ym1 were not significantly 
altered. Of the genes we examined, expression of the chitinase-like protein (CLP) Ym2 
(Chitinase 3-like 4) was significantly increased in response to caspofungin. In contrast, none 
of the genes we examined in wild-type caspofungin-treated mice displayed significant 
changes in expression in the absence of γδ T cells (Fig. 8B). Therefore, caspofungin 
treatment and γδ T cells may influence eosinophil recruitment and pathology by an 
undescribed, novel pathway.
Discussion
This study is the first to demonstrate a link between caspofungin-mediated increases in 
chitin exposure and detrimental eosinophil activation in mice and humans with aspergillosis. 
Previous studies detailed the in vitro “paradoxical effect” of fungal growth in the presence of 
high levels of caspofungin (20, 54), and a recent study demonstrated increased chitin 
synthase activity and fungal stress response activation in response to caspofungin that 
permits A. fumigatus growth despite the presence of drug-mediated cell wall remodeling 
(55). These in vitro results are supported by in vivo evidence from Moretti et al that 
demonstrated decreased caspofungin efficacy in mice with IA (20, 40). Similar to our 
results, they reported mouse strain-dependent differences in fungal burden, with BALB/c 
mice most susceptible to infection at any dose of caspofungin, and C57BL/6 mice exhibiting 
a drug dose-dependent response. In our study, only BALB/c mice displayed both increased 
fungal burden and eosinophil recruitment in response to caspofungin (Figs. 2 and 4). 
However, eosinophil-deficient mice from either background exhibited decreased fungal 
burden in response to caspofungin (Figs. 4 and S1). Therefore, despite differences in 
recruitment, eosinophils were detrimental to effective fungal clearance in caspofungin-
treated BALB/c or C57BL/6 mice. Future studies will require consideration of these 
differences as mice with specific gene-targeted deficiencies are used from either background 
in order to elucidate mechanistic pathways of eosinophil-mediated pathology.
In addition to reporting increased mouse fungal burden in IA after caspofungin therapy, 
Moretti et al also provided mechanistic data that demonstrated a requirement for TLR2, 
TLR9, and Dectin-1 (40). Interestingly, TLR2 and TLR9 expression were required for 
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macrophage secretion of IL-17A and IL-10 in response to purified chitin particles (56, 57). 
Other studies have shown roles for NOD2, mannose receptor, and FIBCD1 in chitin binding 
or chitin-mediated responses (56–58). In contrast to Moretti et al, our results did not show a 
significant decrease in fungal burden with high-dose (5 mg/Kg) caspofungin in dectin-1−/− 
mice (Supplemental Figs. S1D–F). Interestingly, Moretti et al reported increased neutrophils 
in the lungs of high-dose caspofungin-treated animals with IA (40), and these cells are 
known to express high levels of dectin-1 (59). However, in contrast to the cyclophosphamide 
induced immune suppression used in that study, we depleted neutrophils prior to and during 
infection. It is thus possible that neutrophils and dectin-1 recognition contribute to 
paradoxical caspofungin activity when present in mice with IA. We chose the neutropenic 
model of IA because it is considered one of the best methods to increase host susceptibility 
to IA while still preserving the ability to determine the contributions of specific cell 
populations (e.g. eosinophils) that may otherwise be affected by broad immune suppressants 
such as cyclophosphamide (60–63). It is therefore likely that co-recognition of β-glucan and 
chitin in paradoxical caspofungin activity and eosinophil pathology is a complex 
multivariate process that will require considerable resources to delineate, and will remain an 
active and important area of future investigation.
Although we observed that caspofungin-mediated airway eosinophil recruitment and 
pathology in IA was partly dependent on γδ T cells, the mechanism driving this phenotype 
remains unknown. The role of γδ T cells in lung eosinophil recruitment in our model is in 
contrast to the immune response to purified chitin particles that was mediated by type 2 
innate lymphoid cell (ILC2) production of IL-4 and IL-13 (64). As noted in our discussion 
of pattern recognition receptors, it is possible that composite recognition of multiple fungal 
PAMPS also results in an increased role for γδ T cells in lung eosinophil recruitment and 
that these pathways are not sufficiently activated in response to chitin alone in the presence 
of ILC2s. Surprisingly, detection of lung γδ T cells was decreased in caspofungin-treated 
mice with IA when compared to untreated mice (Figs. 6A and 6B). It is possible that both 
CD3 and TCR levels were decreased to levels that rendered activated γδ T cells 
undetectable by flow cytometry (51–53). We did not detect any significant shift in median 
fluorescence intensity in lung γδ T cells in either the CD3 or TCRδ channels with 
caspofungin treatment (data not shown), although it is still possible that these cells remain 
despite a lack of detection. Furthermore, our results did not indicate a change in IL-4 
activation in lung γδ T cells with caspofungin treatment, and no significant changes among 
a panel of effector cytokines, chitinases, and other markers of type 2 immunity (Figs. 6 and 
8A). Rather, the chitinase 3-like 1/Ym2 was the only gene in our panel with increased 
expression with caspofungin therapy, and this pattern may be altered in the absence of γδ T 
cells (Fig. 8). Ym2 is a chitin binding protein that lacks chitinase activity and is thought to 
promote lung type 2 immunity (65). However, the understanding of the roles of this 
molecule in human infection and disease is preliminary. Future studies will require isolation 
of γδ T cells in untreated and caspofungin-treated mice with IA to compare changes in 
expression of these and other immune effectors, with the role of those identified pathways 
validated with knockout mice and adoptive transfer experiments.
Eosinophils have long been described as end-stage effector cells that secrete an array of 
cyototoxic proteins and lipid mediators that promote inflammation and collateral destruction 
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of surrounding tissues. However, more recent studies have elucidated homeostatic and 
immunoregulatory roles for eosinophils (66, 67). It is unclear which role is most relevant in 
our caspofungin-increased pathology model or in patients with IA. Our analysis of 
eosinophil granule proteins in patients treated with caspofungin was limited by relatively 
low numbers of caspofungin-treated patients in the lung transplant cohort (n=6) and the 
large range and non-normal distribution of values of eosinophil activation markers in each 
group. These patients had a variety of disparate underlying conditions that necessitated lung 
transplant, the most common being cystic fibrosis and chronic obstructive pulmonary disease 
(COPD), two diseases with very distinct etiologies that develop at different stages of life. In 
addition, many of these patients were treated with multiple immune suppressive and 
antimicrobial drugs and/or may have exhibited sequelae of atopy or other infections that 
could influence levels of eosinophil activation independent of caspofungin. Despite 
potentially confounding factors inherent in human samples, we observed an increased 
detection of MBP and EPX in the BALF of fungal-infected patients that received 
caspofungin therapy when compared to those that received azoles. Future studies with paired 
samples (pre/post caspofungin treatment) will be necessary to determine the full contribution 
of these factors to eosinophil activation as well as the association of this activation with 
severity of disease in patients with IA or in other cohorts with marked eosinophil activation, 
such as allergic bronchopulmonary aspergillosis (ABPA) patients.
Since our results highlight the possibility that antifungal cell wall modulation could promote 
detrimental immunity in some patients, we encourage others to consider this potential host-
pathogen relationship in studies that examine antimicrobial mechanisms of protection in 
susceptible hosts. It is likely that some combinations may prove complimentary. For 
example, caspofungin therapy could be combined with the chitin-synthesis inhibiting 
antifungal nikkomycin z to counteract increased chitin and detrimental eosinophilia induced 
by increased caspofungin (36, 68). However, in the absence of more specific clinical data, 
we do not believe that any risk of eosinophil pathology in caspofungin-treated patients 
currently outweighs the potential benefits of prophylactic or salvage therapy with 
echinocandins. The continued investigation of the potential of therapies that target 
eosinophil recruitment and activation along with fungal growth and dissemination in patients 
with fungal infection thus remains an important endeavor.
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FIGURE 1. 
Caspofungin increases surface chitin exposure in A. fumigatus in vitro and in the lungs of 
mice with IA. (A and B) Af293 conidia were cultured and germinated (4h at 37°C) in the 
presence of caspofungin or control conditions, then fixed prior to WGA-APC staining. (A) 
Representative histogram overlay from 3 experiments. (B) Summary of median fluorescence 
intensity of WGA staining from 3 experiments (n=3/group). (C) Infection timeline. BALB/c 
mice were depleted of neutrophils and infected with 5x106 Af293 conidia, with a subset of 
mice treated with i.p. caspofungin daily until harvest at 72h post-infection. (D) 
Representative fungal morphology in GMS-stained control lung and caspofungin-treated 
mice. Red arrows highlight swollen or burst hyphal tips, blue arrows highlight short, 
thickened hyphae. Panels are representative of sections from 3 mice/group. (E) 
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Representative immune fluorescence staining of d3 frozen lung sections from caspofungin 
treated or untreated mice with IA, stained for CCR3+ cells (green) and calcofluor white 
(red) to identify fungal chitin (n=3/group). Scale bars (D, E) are equivalent to 20 μm. 
****p<0.0001.
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FIGURE 2. 
Airway eosinophil accumulation is increased with caspofungin treatment in mice with IA. 
A, B, and C, BALB/c mice were neutrophil-depleted, infected, and treated or untreated with 
caspofungin as described for Fig. 1 (timeline in Fig. 1C). BALF was analyzed for eosinophil 
recruitment as described in Materials and Methods. D and E, analysis of BALF from 
caspofungin-treated mice with IA that constititively express lung AMCase (SPAM+) 
compared to transgene-negative littermates (SPAM-). A, representative flow plots depicting 
gating of BALF CD45hiLy6G−SiglecF+CD11c− eosinophils (Eos) and 
CD45hiLy6G−SiglecF+CD11c+ alveolar macrophages (AM). B and D, total cells. C and E, 
frequency (left) and total number (right) of eosinophils. Data shown are a summary of 2–3 
experiments. *p<0.05. **p<0.01.
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FIGURE 3. 
Increased detection of eosinophil granule proteins in aspergillosis patients treated with 
caspofungin. Major basic protein (A) and eosinophil peroxidase (B) in the BALF of lung 
transplant patients with or without aspergillosis quantified by ELISA. Patients were further 
subdivided by antifungal therapy: those that received azoles (Infected) or those that received 
caspofungin alone or in combination with azoles (Inf+Caspo). Statistical analysis was 
performed as described in Materials and Methods.
Amarsaikhan et al. Page 19
J Immunol. Author manuscript; available in PMC 2018 July 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
FIGURE 4. 
Increased disease severity and lack of fungal clearance in caspofungin-treated mice is 
eosinophil-dependent. Wild-type BALB/c or eosinophil-deficient (ΔdblGATA1) mice were 
infected and treated or left untreated with caspofungin as described for Fig. 1. (A) Survival. 
(B) Disease Score. (C) Fungal DNA (burden) (15–30 mice/group, summary of 3–6 
experiments). (A–C) n=15–30 mice/group, data are a summary of 3–6 experiments. (D) 
Change in fungal DNA burden with caspofungin treatment calculated from results shown in 
Fig. 4A. (E) Fungal burden as measured by quantification of GMS staining of histological 
sections (n=3–4 mice/group). (F) Representative GMS staining of histological sections from 
wild-type (top) or eosinophil−/− mice (bottom). Scale bar is equivalent to 100 μm. *p<0.05. 
**p<0.01. ****p<0.0001.
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FIGURE 5. 
Disease severity, fungal burden, and eosinophil recruitment are not increased in 
caspofungin-treated RAG1−/− mice. Mice deficient in RAG1 (BALB/c background) were 
infected with A. fumigatus as described for Fig. 1. (A) Disease severity and (B) Fungal 
burden (n=8). (C) Frequency (left) and total BALF eosinophils (right). Data shown are a 
summary of two experiments.
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FIGURE 6. 
Modulation of CD3+TCRδ+ cells in caspofungin-treated mice with IA. Neutropenic mice 
were infected and harvested at 48 hours post-infection, with cell suspensions derived from 
lung homogenates analyzed by flow cytometry for expression of γδ T cell markers. A) 
Representative dot plots from two experiments. B) Frequency (left) and total numbers (right) 
of lung CD3+TCRδ+ cells. C) Representative histogram from two experiments depicting 
GFP fluorescence of CD3+TCRδ+ cells from IL4-GFP-reporter mice (4get). *p<0.05.
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FIGURE 7. 
Caspofungin-mediated eosinophil recruitment and pathology require γδ T cells. γδ T cell-
deficient mice were infected with Af293, monitored and harvested as described for Fig. 1. 
(A) Survival (n=9–10, summary of two experiments). (B) Display of fungal burden 
determined by PCR quantification of fungal DNA (7–8mice/group, summary of two 
experiments). (C) Representative GMS staining of lung sections from γδ T cell-deficient 
mice with the indicated treatment. Scale bar is equivalent to 100 μM. X. Inset, bottom left of 
right panel, determination of fungal burden by quantification of GMS staining in treated and 
untreated mice. (D, E) BALF cell populations as determined by flow cytometry. (E) 
Frequency (left) and total number (right) of airway eosinophils in the indicated experimental 
groups. Data shown are a summary of two experiments. *p<0.05. **p<0.01. ***p<0.001.
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FIGURE 8. 
Effects of caspofungin treatment and requirement for γδ T cells in lung expression of 
immunomodulatory genes in mice with IA. Neutropenic C57BL/6 (B6) wild-type or γδ T 
cell-deficient mice were infected with A. fumigatus, treated or untreated with caspofungin, 
and harvested for qRT-PCR analysis of the indicated genes in lung homogenate extracts at 
48 hours post-infection. A) Wild-type B6 mice treated or untreated with caspofungin. B) 
Wild-type or TCRδ−/− mice infected and treated with caspofungin. *p<0.05.
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